Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Site-directed RNA editing using endogenous ADAR enzymes recruited by short guide RNAs enables programmable adenosine-to-inosine edits in cellular transcripts…
Roche struck a strategic collaboration with Seattle-based Shape Therapeutics worth more than $3 billion to develop RNA editing therapeutics and AAV gene…
October 3, 2024: ShapeTX released two preprints detailing advances to its RNAfix RNA-editing platform, including the DeepREAD AI model for designing ADAR guide…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Roche entered a multi-year strategic collaboration and license agreement with Shape Therapeutics (ShapeTX) in August 2021 for next-generation AAV gene therapies and RNA editing therapeutics targeting Alzheimer's disease, Parkinson's disease and rare CNS diseases, pairing ShapeTX's RNAfix ADAR-recruiting RNA-editing platform and AAVid tissue-targeted capsid library with Roche's neuroscience and rare-disease development expertise. Total potential value exceeds $3B across upfront, research funding and development/regulatory/commercial milestones plus tiered royalties. On November 30, 2023 the partners expanded the alliance, with Roche adding a new target and initiating a program to develop a potential one-time therapy for an undisclosed disease affecting millions of people worldwide; the expansion carried a new initial milestone payment plus additional development, regulatory and sales milestones and tiered royalties. ShapeTX subsequently disclosed further AI-platform advances (DeepREAD guide-RNA design model and an enhanced U7 expression system) in October 2024.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Shape Therapeutics Inc. (this deal) | 2021 | $3.0B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2021 deals · Roche Holding AG deals · Neurology deals